Thiogenesis Therapeutics Corp · TSXV:TTI
Thiogenesis Therapeutics — Investor Presentation (October 2026)
14 slides from Thiogenesis Therapeutics's investor presentation, October 2026
Slide 1: Thiogenesis Therapeutics Corp.
THiogenesiS THerapeuticS Thiogenesis Therapeutics Corp. (TSXV: TTI / OTCQB: TTIPF) Next Generation Treatment for Cystinosis and Beyond October 2026
Slide 2: Forward-Looking Statement
L E GAL Forward-Looking Statement This document and any attachments are intended for information purposes only and should not be construed as an offer or solic itation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain securit
Slide 3: Cystinosis: Effective Therapy, Unmet Need
UN D E R ST A ND I NG T H E D IS E AS E Cystinosis: Effective Therapy, Unmet Need What is Cystinosis A rare genetic disorder in which toxic cystine builds up inside cells' internal “waste bins” (lysosomes), leading to progressive kidney failure and organ damage in children Current Treatment Burden S
Slide 4: Thiogenesis — Overview
O VE R V IE W Thiogenesis — Overview Clinical-stage biotech company developing next-generation cysteamine therapies for cystinosis and primary mitochondrial diseases Proven team Developed Procysbi® for cystinosis at Raptor ($800M acquisition) Next-generation prodrug TTI-0102 — next-generation, susta
Slide 5: Proven Leadership / Cysteamine Experience
T E AM Proven Leadership / Cysteamine Experience Christopher M. Starr, PhD — Chairman of the Board Co-founder, BioMarin; co-founder & CEO, Raptor; co-founder, Monopar Patrice Rioux, MD, PhD — Founder, CEO, Director Former Biogen; CMO/Head of Regulatory at Raptor Deep experience at the intersection o
Slide 6: TTI-0102: Human PK and Safety
P H AS E 1 ST U D Y (PK / S AF E T Y) TTI-0102: Human PK and Safety Evaluated at up to 4× the therapeutic dose Well-tolerated in healthy volunteers Up to 4× the therapeutic dose Mild side-effect profile Only mild, short-term body odor — no other significant side effects Sustained drug levels through
Slide 7: Adherence Failure Drives Kidney Failure
T H E CO R E P R OB L E M Adherence Failure Drives Kidney Failure Compounding Organ Damage >90% ~70% Because cysteamine does not reverse established proximal tubular damage, unmanaged days accumulate directly as permanent nephron scarring. Adherence in children under direct Adherence in self-managin
Slide 8: A De-Risked Path to Cystinosis Phase 3
P AT H T O PH A S E 3 A De-Risked Path to Cystinosis Phase 3 Rapid, low-risk path to market Senior team brought Procysbi® to market (Clinical & Regulatory, CMC) Established cysteamine biology and mechanism of action — approved 2× Established clinical endpoints for approval — surrogate biomarker Inve
Slide 9: Primary Mitochondrial Diseases
UN D E R ST A ND I NG T H E D IS E AS E Primary Mitochondrial Diseases Rare genetic diseases/mutations Impair the body's ability to efficiently produce cellular energy and release significant free radicals – generating oxidative stress and inflammation Patient population Approximately 75,000 patient
Slide 10: Leigh Syndrome
NE X T S T EP IN VA LI D AT I ON Leigh Syndrome Next step in mitochondrial disease execution Subgroup of Primary Mitochondrial Disease Caused by a genetic mutation that impairs the cell’s ability to produce ATP Birth prevalence: ~1 in 40,000 live births FDA-cleared IND For a two-stage Phase 2a clini
Slide 11: Thiogenesis Development Pipeline
P LA T FO R M Thiogenesis Development Pipeline TTI-0102 Indication Preclinical Phase 1 Phase 2 Phase 3 Cystinosis ✓ ✓ Investigator Initiated Study Next (Lysosomal Storage Disease) Leigh Syndrome ✓ ✓ 2a Planned (Q4-2026) (Primary Mitochondrial Disease) MELAS ✓ ✓ ✓ Complete (Primary Mitochondrial Dise
Slide 12: Summary of Investment Thesis
O VE R V IE W Summary of Investment Thesis Near-term value creation, long-term platform opportunity Proven cysteamine development team, with a track record of value creation Institutions have validated the opportunity Leading rare disease KOLs engaged in clinical development Established path toward
Slide 13: Company Info
C OR P O R AT E S NA PS H O T Company Info Shares Issued 69.9 million Shares Fully Diluted 76.2 million Insiders (24%) 16.9 million Share Price (04/09/2026) $0.50 52-Week High/Low $0.88 / $0.44 Market Cap. $35.0 million Cash (06/30/2026) $7.3 million Contact info@thiogenesis.com Thiogenesis Therapeu
Slide 14: Established Market, Durable IP
A PP E ND IX 1 Established Market, Durable IP Commercial Market Dynamics Intellectual Property Protection $233M US Procysbi® sales in FY2025 (per Amgen 10-K) at $300k– Composition of Matter: US 11,786,491 B2 and granted EU $500k+/patient/year with proven, entrenched reimbursement counterpart (WO2017
Thiogenesis Therapeutics — Investor Presentation (October 2026) on 6ix